MedTrace Logo

PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies

NCT03044743 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-05-02

No results posted yet for this study

Summary

This study will evaluate the safety of PD-1 knockout EBV-CTL cells in treating EBV (Epstein-Barr virus) positive advanced stage malignancies. Blood samples will also be collected for research purposes.

Conditions

  • Stage IV Gastric Carcinoma
  • Stage IV Nasopharyngeal Carcinoma
  • T-Cell Lymphoma Stage IV
  • Stage IV Adult Hodgkin Lymphoma
  • Stage IV Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Fludarabine

To modify immune micro-environment

DRUG

Cyclophosphamide

To modify immune micro-environment

DRUG

Interleukin-2

To sustain the survival of infused T cells

Sponsors & Collaborators

  • Yang Yang

    lead OTHER

Principal Investigators

  • Baorui Liu, MD · The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-07
Primary Completion
2020-03-31
Completion
2022-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03044743 on ClinicalTrials.gov